A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms FIND-CKD
- Sponsors Bayer
Most Recent Events
- 21 Aug 2024 Planned primary completion date changed from 12 Jan 2026 to 5 Jan 2026.
- 09 Nov 2023 Planned number of patients changed from 1580 to 1584.
- 18 May 2023 Status changed from recruiting to active, no longer recruiting.